Market Cap (In EUR)
29.88 Million
Revenue (In EUR)
9.05 Million
Net Income (In EUR)
-5.07 Million
Avg. Volume
584.00
- Currency
- EUR
- Country
- Healthcare
- Open
- -
- Prev. Close
- -
- Day Range
- -
- Year Range
- 2.08-13.6
- PE
- -
- EPS
- -
- Beta Value
- 0.206
- ISIN
- FR0014007ZB4
- CUSIP
- -
- CIK
- -
- Shares
- -
- Earnings Annoncement
- -
Company Profile
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Dr. Pier Vincenzo Piazza M.D., Ph.D.
- Employee Count
- -
- Website
- https://www.aelisfarma.com
- Ipo Date
- 2022-02-18
- Details
- Aelis Farma SA, a biotechnology company, engages in the research and development of treatments for brain diseases. It is developing signaling-specific inhibitors of the CB1 receptors, such as AEF0117, a drug candidate, which is in Phase 2b clinical trials for the treatment of the harmful effects of excessive cannabis use; and AEF0217, a drug candidate, which completed Phase 1 clinical trials to treat cognitive deficits observed in Down syndrome, as well as other cognitive impairments. The company was incorporated in 2013 and is based in Bordeaux, France.
More Stocks
-
0236
-
HTLD
-
605277Xinya Electronic Co., Ltd.
605277
-
002511C&S Paper Co.,Ltd
002511
-
GMFI
-
TULIVETulive Developers Limited
TULIVE
-
TGNTTotaligent Inc.
TGNT
-
PAYTM